Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiomarkerOCT: Serum and OCT Biomarkers in DME
NCT06984822Recruiting
- Sponsor
- Region Västra Götaland
- Start
- Aug 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Open-label trial in diabetic macular edema (DME) (3 arms), sponsored by Region Västra Götaland. Primary endpoints: Serum levels of Vascular Endothelial Growth Factor at 4 weeks, Serum levels of interleukin 6 at 4 weeks and 6 more. Started Aug 2025; status: recruiting.
02
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06984822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06984822.